Anaphylactoid reactions associated with bisantrene infusions.
Nine of ninety-three patients receiving Bisantrene on an every three week schedule developed an anaphylactoid reaction with a variety of symptoms. Most reactions occurred in patients who had multiple exposures to Bisantrene. Investigators utilizing Bisantrene in ongoing clinical trials should be aware of this life threatening toxicity.
D000707:Anaphylaxis / Q000139:chemically induced*; D000873:Anthracenes / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D007263:Infusions, Parenteral; D009369:Neoplasms / Q000188:drug therapy
D000873:Anthracenes; C031404:bisantrene